Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 63/082,168, filed Sep 23, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,795,168 | Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | ||
| US 12,454,532 | Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | ||
| Application 19/237,221 | Inhibiting G Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP) Pending Not granted | Forma Therapeutics, Inc. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Forma Therapeutics, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.